Hypertrophic cardiomyopathy (HCM) is a common inherited heart disease with a prevalence of at least 1 in 500. Presentation is highly variable even within families, and although the majority of affected individuals lead a normal life, some develop severe, progressive heart failure symptoms, angina, or arrhythmia, and others die suddenly, either with or without previous symptoms. Left ventricular outflow tract (LVOT) obstruction occurs in two-thirds of patients either at rest or after provocation and can be improved by negatively inotropic drugs, surgical septal myectomy, or alcohol septal ablation 1 . Patients judged to be at high risk of sudden death from mutations might lead to new and widely applicable therapies. Most of the mutations act as dominant negatives; they produce poisoned peptides, in which the mutant polypeptide produced disrupts the activity of the wild-type gene. An exception is the truncation mutations in MYBPC3 in which haploinsufficiency (a reduction in protein production) has been shown. In myectomy specimens from patients with an MYBPC3 truncation mutation, protein content was reduced by 24-33% compared with donor or non-MYBPC3 myectomy specimens 6, 7 . Abstract | Evidence indicates that anatomical and physiological phenotypes of hypertrophic cardiomyopathy (HCM) stem from genetically mediated, inefficient cardiomyocyte energy utilization, and subsequent cellular energy depletion. However, HCM often presents clinically with normal left ventricular (LV) systolic function or hyperkinesia. If energy inefficiency is a feature of HCM, why is it not manifest as resting LV systolic dysfunction? In this Perspectives article, we focus on an idiosyncratic form of reversible systolic dysfunction provoked by LV obstruction that we have previously termed the 'lobster claw abnormality' -a mid-systolic drop in LV Doppler ejection velocities. In obstructive HCM, this drop explains the mid-systolic closure of the aortic valve, the bifid aortic pressure trace, and why patients cannot increase stroke volume with exercise. This phenomenon is characteristic of a broader phenomenon in HCM that we have termed dynamic systolic dysfunction. It underlies the development of apical aneurysms, and rare occurrence of cardiogenic shock after obstruction. We posit that dynamic systolic dysfunction is a manifestation of inefficient cardiomyocyte energy utilization. Systolic dysfunction is clinically inapparent at rest; however, it becomes overt through the mechanism of afterload mismatch when LV outflow obstruction is imposed. Energetic insufficiency is also present in nonobstructive HCM. This paradigm might suggest novel therapies. Other pathways that might be central to HCM, such as myofilament Ca 2+ hypersensitivity, and enhanced late Na + current, are discussed.
1
. Patients judged to be at high risk of sudden death from mutations might lead to new and widely applicable therapies. Most of the mutations act as dominant negatives; they produce poisoned peptides, in which the mutant polypeptide produced disrupts the activity of the wild-type gene. An exception is the truncation mutations in MYBPC3 in which haploinsufficiency (a reduction in protein production) has been shown. In myectomy specimens from patients with an MYBPC3 truncation mutation, protein content was reduced by 24-33% compared with donor or non-MYBPC3 myectomy specimens 6, 7 .
In vitro experiments on preparations from mutant HCM cardiomyocytes have produced strikingly contrasting results; both gain and loss of contractile function have variously been demonstrated 8 . See, for example, the compilation of disparate results published just for the R403Q mutation in MYH7, which encodes myosin 7, the cardiac β-myosin heavy chain protein 9 . Force generation with exposure to Ca 2+ and the degree of leftward displacement (in most mutations) of force-Ca 2+ curves is the method of determination. The difference between experiments might depend on intrinsic differences in the mutations, but also on the wide variety of experimental models used. Early experiments with the myosin heavy chain mutant R403Q showed loss of function, leading to the hypothesis that hypertrophy was a compensation for decreased force generation; others have shown increased sensitivity 8 . Subsequent work with thin filament mutations showed increased Ca 2+ sensitivity of force generation 8 . Despite the bewildering array of differing functional results, two pathophysiological pathways from sarcomeric mutations to a HCM phenotype have been consistently experimentally validated: first, inefficient energy utilization (energy wasting for tension development) and, second, increased myofilament Ca 2+ sensitivity. In this Perspectives article, we focus primarily on the energy depletion hypothesis, but we also summarize the evidence for Ca 2+ sensitization, and discuss how the two theories overlap. Increasing evidence indicates that energy depletion has an important role in the development of hypertrophy and in ventricular fibrillation can be treated with an implanted defibrillator, most often as primary prevention, or for secondary prevention after surviving a potentially lethal ventricular arrhythmia 2, 3 . A crucial advance in our understanding of HCM was made in 1990 with the first report of a disease-associated mutation 4 . Subsequently, multiple disease-associated mutations have been discovered, most coding for sarcomeric proteins 5 . Mutations in multiple genes, encoding sarcomeric or nonsarcomeric proteins, lead to similar clinical manifestations; this observation gives hope that understanding the final common pathways that link known disparate Abstract | Evidence indicates that anatomical and physiological phenotypes of hypertrophic cardiomyopathy (HCM) stem from genetically mediated, inefficient cardiomyocyte energy utilization, and subsequent cellular energy depletion. However, HCM often presents clinically with normal left ventricular (LV) systolic function or hyperkinesia. If energy inefficiency is a feature of HCM, why is it not manifest as resting LV systolic dysfunction? In this Perspectives article, we focus on an idiosyncratic form of reversible systolic dysfunction provoked by LV obstruction that we have previously termed the 'lobster claw abnormality' -a mid-systolic drop in LV Doppler ejection velocities. In obstructive HCM, this drop explains the mid-systolic closure of the aortic valve, the bifid aortic pressure trace, and why patients cannot increase stroke volume with exercise. This phenomenon is characteristic of a broader phenomenon in HCM that we have termed dynamic systolic dysfunction. It underlies the development of apical aneurysms, and rare occurrence of cardiogenic shock after obstruction. We posit that dynamic systolic dysfunction is a manifestation of inefficient cardiomyocyte energy utilization. Systolic dysfunction is clinically inapparent at rest; however, it becomes overt through the mechanism of afterload mismatch when LV outflow obstruction is imposed. Energetic insufficiency is also present in nonobstructive HCM. This paradigm might suggest novel therapies. Other pathways that might be central to HCM, such as myofilament Ca 2+ hypersensitivity, and enhanced late Na + current, are discussed.
the wider pathophysiology of HCM [9] [10] [11] [12] [13] [14] [15] . We summarize this evidence, and then discuss the phenotypic manifestations of energy depletion in three realms of cardiac function: diastolic dysfunction, dynamic systolic dysfunction (especially against imposed afterload), and arrhythmogenesis. In particular, we show how patients with HCM experience a highly idiosyncratic form of systolic dysfunction, which we posit is best explained by inefficient utilization of energy.
Energy depletion, HCM, and diastole
The theory that the failing heart is running out of fuel is a longstanding one, going back to the early twentieth century 11 . The energy turnover of the normal heart can only be described as extravagant. The daily cardiac turnover of ATP, an astonishing 6 kg, is very many times the mass of the heart itself, and its myocardial ATP pool 16 . In <10-15 s, the total amount of ATP present within a myocyte is consumed by myocardial work and requires constant replenishment 17 . High energy needs make the myocardium sensitive to genetic and acquired perturbations in energy supply, and to inefficiency in its utilization, which result in the HCM phenotype in some patients 12, 13 . The rationale for inefficient energy utilization as a cause of the HCM phenotype rests on several lines of evidence.
First, high-energy phosphate metabolism can be assessed in vivo in the heart using 31 P-magnetic resonance (MR) spectroscopy. Investigators compared the cardiac phosphocreatine (PCr) to ATP ratio in 31 patients harbouring mutations in the genes for either β-myosin heavy chain, cardiac troponin T, or myosin-binding protein C, and in 24 control individuals. The PCr/ATP ratio was reduced in the patients with HCM by 30% relative to controls, and the reduction was of a similar magnitude in all three disease-gene groups, and not related to the degree or presence of hypertrophy 13, 17 . ATP is produced in the mitochondria, but is used elsewhere, mainly by sarcomeric proteins and ion transporters. PCr, the most abundant high-energy phosphate in the heart, acts as an energy shuttle and as an energetic reserve, moving high-energy phosphate from the mitochondria to sites of utilization. In heart failure, cytosolic levels of ATP are generally zealously maintained, whereas PCr levels fall 18, 19 . Second, PET scanning using clearance of 11 C-acetate as a semiquantitative measure of myocardial oxygen consumption has shown reduced consumption in patients elevation of Ca 2+ is a known trigger for activation of calcineurin, which is an effector of hypertrophy. In iPSC-derived HCM myocytes, inhibition of calcineurin, and also of cellular Ca 2+ inflow by verapamil, reduced hypertrophy 31 . Multiple converging, genetically mediated metabolic pathways that are associated with an increased energetic cost of tension development, therefore, lead to the hypertrophic phenotype: classic autosomal dominant HCM sarcomeric mutations, defective cellular energy-sensing machinery, autosomal recessive Friedreich ataxia, and genetic morphologically and functionally disordered mitochondria.
Passive viscoelastic properties of human HCM cardiomyocytes are similar to those of normal hearts and so cannot account for increased stiffness of HCM hearts 32 . Diastolic relaxation is a highly energydependent process; diastolic dysfunction owing to impaired relaxation is the most common phenotypic physiological abnormality in patients with HCM 33 , and diastolic dysfunction has been associated with abnormal energetics in experimental models of HCM 9, 34, 35 . The additional demonstration of diastolic dysfunction in HCM phenocopies and in Friedreich ataxia 36, 37 has driven development and acceptance of the theory that energetic impairment, hypertrophy, and diastolic dysfunction are causally linked 23 . Alternative explanations have been advanced. Mutant myofilament Ca 2+ sensitivity directly causes diastolic dysfunction, and desensitization has been shown to improve it 38 . Studies in phosphorylation-deficient Mybpc3 mice suggest an important role for protein kinase A-mediated phosphorylation of this protein to enhance lusitropy 39 . The enhanced late Na + current observed in HCM increases cytosolic Ca 2+ , which increases cross-bridging and directly slows diastolic relaxation 40 .
Systolic dysfunction

At rest
If energy insufficiency is a feature of HCM, why is it not manifest as resting systolic dysfunction on echocardiography? Ejection fraction is normal or hyperdynamic in HCM, except infrequently in the 2% of patients who develop transformation into LV hypokinesia owing to diffuse fibrosis 41 . A disparity often exists between the macroscopic assessment of global ejection fraction in patients with HCM who have decreased diastolic volumes, and the with HCM as well as genetic carriers 17, [20] [21] [22] . However, myocardial stroke work was reduced to an even greater extent than oxygen consumption; myocardial efficiency (the ratio of stroke work to myocardial oxygen consumption) was, therefore, decreased. A combined in vitro and in vivo study using tissue of genotype-positive patients with HCM, and PET and cardiac MR scans, revealed an increase in energy tension-cost based on an imbalance between force-generating capacity and ATPase activity 9, 14 . Third, HCM phenocopies, caused by nonsarcomeric protein mutations can develop hypertrophy that resembles HCM, and also have similar flaws in cellular energetics. Examples are a mutation in the γ 2 subunit of 5ʹ AMP-activated protein kinase (AMPK; known as the 'cellular thermostat' because of its central role in energy sensing and regulation) that was found to cause an HCM-like familial syndrome 23, 24 . Similarly, maternally inherited HCM owing to mutations in mitochondrial transfer RNA (tRNA) have been described 25 , with demonstrated defects in oxidative metabolism; all three respiratory chain complexes tested showed reduced activity. Abnormal mitochondrial electron microscopic morphology with disordered function have been described in HCM 26, 27 . Hypokinetic sarcomeres were found in these patients with normal macroscopic LV systolic function, irrespective of the four different mutations studied 7 . Therefore, subclinical systolic LV dysfunction at rest is common in HCM; the underlying substrate for load-induced dynamic systolic dysfunction is present even when global function at rest is normal.
After exercise
Further evidence of latent dynamic systolic dysfunction can be elicited in some patients with HCM after exercise. During exercise, regional and global systolic wall-motion abnormalities can occur in patients with either obstructive or nonobstructive HCM, in the absence of epicardial coronary disease [43] [44] [45] . The question of whether exercise-induced wall-motion abnormalities occur because of energy depletion from inefficient utilization or owing to microvascular ischaemic disease leading to impaired ATP generation is controversial, and is discussed in detail below. Until recently, in vivo assessment of high-energy phosphate stores were performed at rest for technical reasons. Dass et al. studied 35 patients with HCM (of varying genotypes) with a resting outflow gradient <30 mmHg and matched controls, performing MR spectroscopy before and during leg-raise exercise inside the scanner 46 . As expected, the PCr/ATP ratio was lower at rest in patients with HCM. With exercise, the ratio dropped a further 8 ± 17% in patients, but not in controls. The resting energetic impairment did not correlate with the extent of hypertrophy, and only weakly correlated with late gadolinium enhancement.
With imposition of afterload
Three phenomena, with features unique to HCM, illustrate the vulnerability of the energy-inefficient myocardium to the imposition of obstruction and afterload: the mid-systolic drop in LV ejection velocities, apical aneurysm formation in Doppler echocardiography and showed an exacerbation of the reduction in flow after administration of dobutamine 51 . The appearance of the mid-systolic drop in velocities can vary between patients and from hour to hour depending on the severity of the outflow gradient, and the capacity of the left ventricle to overcome the obstruction 49 . However, the timing of the nadir always moves precisely in synchrony with timing of the peak velocity of the continuous-wave Doppler in the outflow tract and, therefore, with peak afterload This observation demonstrates that the lobster claw abnormality is not merely a flow phenomenon, but is caused by myocardial dysfunction (FIG. 3) . Barac and colleagues also showed premature termination of septal contraction with obstruction that was reversed by abolition of obstruction 48 . Ross explained the concept of afterload mismatch as the inability of the left ventricle to "maintain a normal stroke volume against the prevailing systolic load on the left ventricle, and it generally occurs in the setting of limited preload reserve" (REF. 53 ). Afterload mismatch was Ross's term to explain the rapid recovery of poorly mid-cavity obstruction, and rarely, profound systolic hypokinesia, or in extreme cases, cardiogenic shock when latent obstruction becomes persistent and severe.
The 'lobster claw abnormality'. In patients with HCM and a LVOT gradient ≥60 mmHg, an abnormal Doppler ejection velocity pattern occurs in the left ventricle, just below the tips of the mitral valve leaflets and also, therefore, below the site of LVOT obstruction. This phenomenon has been termed the 'lobster claw abnormality' because of its characteristic appearance 47 (FIG. 1) . Early in systole, when the left ventricle is unimpeded, LV ejection velocities are normal (FIG. 2a) . Simultaneously with mitral-septal contact, an abrupt reduction in ejection velocities occurs because of the sudden imposition of afterload (FIG. 2b) . The mid-systolic reduction in ejection velocities is reversed when outflow obstruction is alleviated or abolished 48, 49 . The drop in velocities explains some of the well-recognized clinical features of HCM, for example the biphasic aortic pressure trace (and carotid pulse), and mid-systolic closure of the aortic valve 50 . Conklin and colleagues extended this observation by measuring flow in the proximal descending aorta by Nature Reviews | Cardiology contracting myocardium after relief of outflow obstruction in aortic stenosis 53 . At the time, the actual mechanics of this phenomenon at the myocardial level were unknown. Increasing evidence now shows that aortic stenosis can cause severe energetic insufficiency that is mediated by increased afterload and is normalized after aortic valve replacement. Subclinical LV impairment can be demonstrated during stress, and this impairment responds to surgical correction [54] [55] [56] [57] . Ross contrasted afterload mismatch in aortic stenosis to patients with irreversibly depressed myocardial contractility, whose true (low) ejection fraction is unmasked by correction of the (usually mitral) regurgitation.
In HCM, LV performance can be doubly affected by energy inefficiency. Energy the important clinical observation that angina at rest is uncommon in obstructive HCM. Secondly, substantial evidence indicates that resting ischaemia does not occur in patients with resting obstruction, as assessed using various techniques.
Cannon and colleagues assessed myocardial lactate consumption in the coronary veins. Myocardial lactate consumption at rest was normal, even in the presence of high resting gradients 59, 60 . Lactate production did not occur until atrial pacing commenced 59, 60 . Moreover, resting perfusion defects are not visualized on thallium scintigraphy in the great majority of patients 61 . Only 24% of patients had resting perfusion defects, and these patients had reduced resting systolic function owing to myocardial fibrosis in the end-stage phase of the disease 41 . Additionally, overall resting myocardial blood flow (assessed using PET and 13 N-labelled ammonia) did not differ between patients with HCM and controls (although the vasodilator 'reserve' , assessed using dipyridamole, was blunted) 62 . Accordingly, Crilley et al. showed that the myocardial perfusion reserve index in these patients did not correlate with energy impairment 13 . Carriers of the HCM-associated MYBPC3 mutation have reduced myocardial efficiency in the absence of hypertrophy and microvascular dysfunction 63 . Together with other findings 17 , Timmer and Knaapen concluded that "these results imply that impaired energetics are, at least in part, the direct result of ATP-wastage by mutated sarcomeres, and may precede coronary microvascular dysfunction in the pathophysiological cascade" (REF. 22) .
From this evidence, we believe that the mid-systolic reduction in LV Doppler ejection velocities, which is routinely and universally observed in patients with LVOT gradients of ≥60 mmHg, is not caused by ischaemia, but by another phenomenon. We posit that inefficient utilization of energy in HCM is the cause. When ischaemia is superimposed on top of energetic impairment, the effects on systolic function and diastolic function are adversely synergistic, especially after exercise.
Resting wall-motion abnormalities.
Afterload-induced systolic dysfunction can trigger the occurrence of apical akinetic aneurysm in severe mid-LV obstruction, and heart failure and cardiogenic shock in the most extreme cases. In HCM with mid-LV obstruction, the LV apex can be subjected to very high impedance to depletion can impair diastolic relaxation, which is nearly ubiquitous in HCM, and the effect of the acute imposition of afterload on an energy-depleted left ventricle reduces systolic flow. Together, diastolic and systolic dysfunction contribute to the observed inability to increase stroke volume with exercise, and thereby to symptoms of exercise intolerance and heart failure 58 . Energetic insufficiency can be genetic (HCM) or acquired (aortic stenosis), or be from a combination of both (obstructive HCM).
Energy inefficiency or ischaemia?
Is the mid-systolic drop in ejection velocities and flow simply due to ischaemia from microvascular disease, or to ischaemia from oxygen supply-demand mismatch? We argue that it is due to neither cause. First, there is Nature Reviews | Cardiology ejection, which can lead to an apical akinetic aneurysm 64 . The same mid-systolic drop in LV ejection velocities is seen just before the obstructing segment of the left ventricle (FIG. 4) . The phenotype can be severe, with intrusive heart failure symptoms 65, 66 , and ventricular arrhythmias can occasionally cause sudden death. The apical aneurysm increased the risk of thrombus formation and subsequent stroke or other systemic embolism 66 . These patients are difficult to manage, because symptoms are often refractory to therapy, and they have a significantly worse prognosis than those with isolated apical hypertrophy. In mid-LV obstruction, although afterload mismatch begins the process of apical aneurysm formation, ischaemia owing to supply-demand mismatch and fibrosis can make dyssynergy irreversible. An interesting corollary might be seen in Takotsubo cardiomyopathy; evidence now shows that patients with this (in some ways phenotypically similar) syndrome have severe energetic impairment at presentation, as measured using 31 P-MR spectroscopy, and that metabolic abnormalities persist at 4-month follow-up 67, 68 . When patients with latent LVOT obstruction suddenly develop persistent severe obstruction, systolic wall-motion abnormalities can occur in segments that previously had normal wall motion. Resolution of LVOT obstruction precedes resolution of severe wall-motion abnormalities. Cardiogenic shock is a rare complication of obstructive HCM and usually occurs in the context of reduced preload owing to dehydration. In patients with latent obstruction who suddenly develop a persistently high resting gradient, we have observed progressive LV systolic dysfunction and cardiogenic shock. Although some patients can be rescued with volume loading and negative inotropes 69 , we have seen several individuals in whom this spiral could be arrested only by surgical relief of obstruction 70 . These patients had systolic dysfunction that was disproportionate to the degree of ischaemia manifest on the electrocardiogram, and disproportionate to the minimal rise in cardiac biomarkers. Their syndrome reversed within minutes of surgical relief of LVOT obstruction (FIGS 5, 6 ). Although we cannot exclude additional factors (such as catecholamine or other neurohumoral effects), we believe their dramatic presentation was caused by acute myocardial energy depletion -a concept supported by the rapid reversal after relief of obstruction. 48, 52 . Compensation to afterload in the normal left ventricle is accomplished first by an increase in preload, dilatation of the left ventricle, and a Frank-Starlingmediated increase in contractility; this initial response is followed during the chronic phase by a compensated period marked by LV hypertrophy 75 . In HCM, the capacity of the left ventricle to use preload as compensation can be compromised acutely and chronically because of impaired diastolic function, which could contribute to Normal and impaired responses to afterload. Is it possible that the mid-systolic drop in LV ejection velocities and flow is caused by obstruction alone, without HCM-impaired energetics? Would normal individuals with normal left ventricles have the same degree of mid-systolic drop in the event of severe outflow obstruction? We cannot exclude this possibility. However, previous experiments argue in favour of intrinsic latent myocardial dysfunction having a role in the mid-systolic drop. Experiments in dogs with normal left ventricles showed that, after chronic aortic constriction, stroke volume returned towards normal 71, 72 . Moreover, after angiotensin administration to patients with a spectrum of LV dysfunction, stroke volume fell or remained constant only in those with compromised LV function 73 . In patients with normal left ventricles, stroke volume and stroke work increased. In another study of 12 control patients given low-dose intravenous angiotensin, no change in tissue Doppler echocardiographic velocities was Nature Reviews | Cardiology the observed instantaneous fall in LV stroke volume seen during the mid-systolic drop 51 . Abnormalities from sarcomeric mutations have been shown to affect LV contractile reserve. When isoprenaline was administered to mouse hearts with troponin T mutation I79N, an impaired responsiveness to inotropic stimulation was demonstrated, along with worsening of diastolic function compared with normal controls 76 , and compared with a control troponin mutation with no effect on myofilament sensitivity. The investigators reviewed similar results with other models of sarcomeric HCM, and discussed how the findings could be explained by altered Ca 2+ kinetics, including decreased energetics. . The arrhythmia was monomorphic ventricular tachycardia in 86% of cases, ventricular fibrillation in 9%, and polymorphic ventricular tachycardia in 5%. Younger patients had shorter cycle length ventricular tachycardia, in keeping with the peak incidence of sudden cardiac death in younger patients, and suggesting a genetic modifier of the re-entry circuit. The majority of ventricular tachycardia was monomorphic, and 67% was terminated by antitachycardia pacing 80 . In nine patients with sustained ventricular arrhythmia, Cha et al. found that more than half had monomorphic ventricular tachycardia, which frequently could be terminated (in 94% of patients) by pacing that interrupted re-entrant pathways 81 . Sustained ventricular arrhythmias originate from two mechanisms. First, they originate from micro and macro re-entry. Second, they originate from abnormal automaticity, including triggered activity from early and late afterdepolarizations, and from enhanced pacemakers.
Re-entry
Fibrosis is a common finding in HCM hearts, especially in patients who have died suddenly. Volumetric cardiac MR delayed hyperenhancement (expressed as a percentage of the LV mass) has been associated with sudden cardiac death or aborted sudden death events 82 . The relationship with fibrosis would seem to validate the re-entry mechanism as a cause for monomorphic ventricular arrhythmias in HCM. However, although fibrosis is fairly common in HCM hearts (occurring in 50%), sudden cardiac death is rare, occurring in only 1% per year 2, 3 . Even patients with a level of fibrosis of 15% of LV mass have a rate of sudden cardiac death or aborted sudden death of barely more than 1% per year 82 .
Abnormal automaticity
Ventricular fibrillation or polymorphic ventricular tachycardia occurred in 14-44% of patients analysed after discharge from an implantable cardioverter-defibrillator 80, 81 . These arrhythmias, especially if they occur without preceding premature ventricular
In an earlier study using I79N mice, systolic function was increased compared with controls; however, the inotropic response to isoprenaline was impaired. The increase in LV fractional shortening was 9% versus 26% in controls 77 . Also, four out of 13 of the mice developed global hypokinesia and died. The investigators hypothesized that with increased Ca 2+ sensitivity, the fibres might already be operating at the flat part of the force-pCa relationship 77 . Energetic depletion could also explain this phenomenon.
The integrity of the Frank-Starling mechanism was evaluated in preparations from myectomy specimens of patients with five different HCM-related mutations of either thick or thin filaments 78 . These experiments involved force measurements from single cardiomyocytes. Ca 2+ sensitivity was demonstrated in all 38 patient samples and every mutation. Lengthdependent activation was lower in all HCM samples compared with donor samples. This impairment of the FrankStarling mechanism was normalized when mutant troponin proteins were replaced with wild-type protein. Protein kinase A also increased phosphorylation of myosin-binding protein C and troponin I, and normalized length-dependent activation in the donors with sarcomere-negative HCM and truncating MYBPC3 mutations, but not in HCM caused by missense mutations 78 . The process of phosphorylation by protein kinase A requires ATP for catalysis and, therefore, might depend on energetic state.
In summary, although macroscopic LV systolic function might seem to be normal or even increased in HCM at rest, multiple imaging modalities, including pulsed Doppler, tissue Doppler, strain echocardiography, and cardiac MR strain, have shown subclinical systolic abnormalities at rest in nonobstructive HCM. Imposition of afterload in the form of LVOT obstruction (or in experimental preparations by angiotensin) exacerbates dynamic systolic dysfunction. Given the ample evidence of energetic depletion in HCM, even in nonobstructive disease, we argue that the spectrum of dynamic dysfunction -the mid-systolic drop in LV ejection velocities, the nascent onset of aneurysms in mid-LV obstruction, and (rarely) shock -are caused by exacerbations of chronic energy depletion. 85 . In mouse papillary muscles, myofibril Ca 2+ sensitivity changes the shape of ventricular action potentials, induces greater beat-to-beat variability in action potential durations, and increases dispersion of conduction velocities at fast heart rates, providing an arrhythmogenic substrate 86 . This enhanced arrhythmogenicity was blocked by blebbistatin, a myosin inhibitor that selectively reduces Ca 2+ sensitivity. Linkage of the energy depletion and the Ca 2+ -sensitivity mechanisms was shown by Huke and colleagues 87 . Using a mouse triggers for ventricular arrhythmia are a change in the intracellular environment, either depletion of cytosolic energy stores, increased myofilament Ca 2+ sensitivity, or cytosolic Ca 2+ overload.
Ventricular tachyarrhythmias
Depletion of cytosolic energy stores.
Impairment of resting energetics, exacerbated during exercise, reduces the ATP available for energy-intensive processes elsewhere in the cell. MR spectroscopy has shown that the levels of energetic depletion can compromise SERCA activity because of its extreme energy requirements 8 . Impaired function of this pump leads to increased cytosolic Ca 2+ levels, which results in further Ca 2+ -induced Ca 2+ release via activation of ryanodine receptors, potentially leading to malignant arrhythmias. By analogy, catecholaminergic polymorphic ventricular tachycardia is caused by a gain-of-function mutation in the ryanodine receptor gene (RYR2). Ca 2+ antagonist binding sites on components of voltage-gated Ca 2+ channels were increased by 33% in the right atrial Nature Reviews | Cardiology model of troponin T I79N HCM, they showed that focal energy deprivation underlies ventricular arrhythmia susceptibility in mice with Ca 2+ -sensitized myofilaments. In this model, they found dephosphorylation (loss) of connexin-43 (gap junction α1 protein) that normally promotes gap-junction coupling 88 , with lusitropic effect is the primary end point, an important secondary end point is the effect of this drug on ventricular arrhythmias assessed using a 30-day monitor 86 . Ventricular arrhythmias are the cause of sudden cardiac death in HCM, and the prevention of sudden cardiac death has assumed a central role in HCM clinical care [1] [2] [3] . The widely applied method for prevention of sudden cardiac death is implanted cardioverter-defibrillators (ICDs), but current risk-stratification guidelines have low sensitivity and specificity 2, 3 . This situation can lead to sudden deaths in patients who have not received an ICD, and use of ICDs in patients who never have appropriate discharges of the device. In addition, sudden deaths are rare in patients who have had successful myectomy 1 , but such patients constitute a minority of those with high-risk profiles. An understanding of the basic pathways leading to ventricular arrhythmias will hopefully lead to biological treatments to prevent such deaths, and eventurally preclude the need for ICDs in many patients. A summary of the known pathophysiological mechanisms underlying development of the HCM phenotype is shown in FIG. 7 .
Treatment of energy depletion
In the modern era, specific pathophysiological HCM derangements have been targeted in the preclinical realm, and trials are beginning in patients 15, 93, 94 . Targeting cellular energetic impairment is a promising paradigm in HCM. If substrate utilization can be made more efficient and save more energy, then improved contractile reserve results from the same conditions. Various therapeutic agents affect myocardial metabolic pathways 93 and might prove useful in HCM. Therapeutic efforts in this area are in their infancy, but a positive clinical trial has been published 95 .
A total of 46 patients with symptomatic, nonobstructive HCM were randomly assigned in a double-blind manner to perhexiline (a metabolic modulator) or placebo 95 . Perhexiline has pleiotropic actions including inhibition of long chain fatty acid uptake into the mitochondria by inhibition of carnitine O-palmitoyltransferase 1. In a mouse model of HCM, perhexiline therapy resulted in a metabolic shift from fatty acids to glucose 96 . Energy obtained during glucose oxidation requires less oxygen consumption than fatty acid metabolism, enhancing cardiomyocyte energy efficiency. Despite the lack of LV outflow gradient, patients with HCM consequent focal slowing of conduction and a proarrhythmic state. ATP depletion was the mechanism for rapid connexin-43 dephosphorylation. In this model, therefore, the two proposed pathophysiological effects -increased myofilament Ca 2+ sensitivity and energy depletion -were linked. Sudden cardiac death in athletes during competition can reasonably be understood as an 'energy crisis' in this context 12, 87, 89 . In a mouse model, desensitization to Ca 2+ as a result of gain-of-function mutations in myofilaments prevents development of the HCM phenotype 38 . The diastolic dysfunction and hypertrophy induced by the tropomyosin mutation E180G, which has increased Ca 2+ sensitivity, was reversed by desensitization. The investigators created a double transgenic mouse line, crossing tropomyosin E180G mice with mice expressing pseudophosphorylated cardiac troponin I (S23D and S24D), which has reduced Ca 2+ sensitivity. Pathological hypertrophy did not occur in the double transgenic mice, and LV performance was improved. A small-molecule inhibitor of sarcomeric contractility (MYK-461) prevents development of HCM in mice with a gain-of-function mutation in myosin 90 .
Enhanced late Na + current. Investigators from Florence, Italy have highlighted abnormalities of cardiomyocytes from surgical specimens from patients undergoing myectomy. HCM cardiomyocytes showed prolonged action potential duration owing to increased late Na + and Ca 2+ currents, and decreased repolarizing K + current 40 . These abnormalities led to increased, prolonged Ca 2+ transients, higher diastolic Ca 2+ concentration, early and delayed afterdepolarizations, and arrhythmogenicity. The investigators found increased activity of calmodulin, a calcium-binding messenger protein, which underlies increased phosphorylation of the L-type calcium channel, phospholamban, the ryanodine receptor, and the late Na + channel in the HCM specimens 40 . Sustained activation of calmodulin is driven by increased cytosolic Ca 2+ concentration 40 . Ranolazine partially reversed the increase in the late Na + current, shortened action potential duration, and decreased the frequency of afterdepolarizations 40 . A novel late Na + channel-inhibiting agent eleclazine (GS-6615; Gilead Sciences) is currently under investigation in a multicentre trial 91, 92 . Although its capacity to increase exercise oxygen consumption through a Nature Reviews | Cardiology had a markedly reduced exercise capacity (peak VO 2 ) compared with matched healthy controls, and also had impaired diastolic function measured using tissue Doppler imaging. Participants were followed up for a mean of 16 weeks of therapy. The perhexiline group showed a significant increase in peak VO 2 (the primary end point), and in functional class and quality of life. The heart-rate-normalized time to peak filling (nTTPF), a sensitive marker of early LV filling, was measured using radionuclide ventriculography at rest and during exercise. Whereas healthy controls showed a shortening of nTTPF on exercise, patients with HCM showed an abnormal lengthening, which indicates a profound gain-of-function mutation in myosin, in parallel with reductions in fractional shortening and ATPase activity 90 . The investigators compared gene expression of proteins localized to the mitochondria and found dysregulated gene expression in 20% of genes in R403Q mice and 29% of genes in R453C mice compared with wild type. Early treatment of these mice with MYK-461 reduced the percentage of dysregulated mitochondrial genes to 4% and 8%, respectively. These data demonstrated that correction of gain of function at the myofilament level resulted in a normalized cellular metabolic state. This improvement might stem from more efficient energy utilization and less substrate depletion, impairment of (energy-dependent) LV active relaxation on exercise. This abnormal response was almost normalized with perhexiline, which was associated (presumably causally) with a significant improvement in the cardiac energetic impairment (an increase in PCr/ATP ratio).
Other metabolic agents are being investigated in HCM, although these studies are in an early phase. Trimetazidine is being evaluated in a phase IIb clinical trial 97 of symptomatic patients with nonobstructive HCM, to assess a primary end point of peak VO 2 .
A small-molecule inhibitor of sarcomeric contractility (MYK-461) suppresses HCM development in mice with a Figure 7 | Three proposed central pathophysiological pathways for development of hypertrophic cardiomyopathy phenotype in genetic hypertrophic heart disease. Inefficient utilization of energy by mutant myofilaments leads to energy depletion (detected in patients as a decreased phosphocreatine [PCr]/ATP ratio). Energy depletion is also observed in pheno copies: 5ʹ-AMP-activated protein kinase (AMPK) mutations, Friedreich ataxia, and mitochondrial mutations. Energy depletion pathway (black arrows) results in impaired function of sarco/endoplasmic reticulum calcium ATPase (SERCA, because of its high obligate energy requirements) leading to decreased diastolic uptake of Ca 2+ and cytosolic Ca 2+ overload. In an adverse feedback loop, elevated Ca 2+ level impairs the ryanodine receptor (RyR2) leading to even higher diastolic Ca 2+ levels and ventricular arrhythmias. Energy depletion results in latent global left ventricular dynamic systolic dysfunction, of which the characteristic abnormality is the mid-systolic drop in ejection velocities when obstruction afterload is interposed, although exercise can provoke a hypokinetic response even in nonobstructed patients. Increased cytosolic Ca 2+ can lead to ventricular arrhythmias regardless of the mechanism. Diastolic function is highly energy-dependent and energy depletion is associated with impaired relaxation in sarcomeric hypertrophic cardiomyopathy and the phenocopies. Myofilament Ca 2+ sensitivity (blue arrows) directly causes inefficient energy utilization and depletion, directly impairs diastolic function, and is arrhythmogenic. Increased cytosolic Ca 2+ can signal upregulated transcription through mediators of calmodulin (calcium/ calmodulin-dependent protein kinase II; CaMKII) or calcineurin. Ca 2+ overload acting through calmodulin (red arrows) enhances late Na + channel and cytosolic Na + , which -through the reciprocal exchange pumps in the sarcoplasmic reticulum and cell membrane -results in Ca or directly from correction of the myofilament gain of function.
Inhibition of the late Na
+ current Ranolazine has pleiotropic effects, including inhibition of the late Na + current. A study of its use in cardiomyocytes obtained from myectomy showed beneficial effects on the contraction-relaxation cycle, which were attributed to improvements in Ca 2+ signalling rather than a metabolic effect 40, 98 . The novel agent eleclazine (GS-6615), which inhibits the late Na + current, is currently under investigation in the multicentre LIBERTY-HCM trial 91, 92 . In a pilot trial, researchers investigated whether oral diltiazem attenuated disease progression in patients with preclinical HCM and an identified genetic mutation 99 . LV end-diastolic diameter improved in the diltiazem group, but decreased further in controls.
Potential future applications
The mid-systolic drop reflects a 'tug-of-war' between the contractile force of the left ventricle and the afterload imposed by obstruction. Its extent, the percent drop to the nadir, and the absolute velocity of the nadir, might be used to assess the inotropic state of the left ventricle to any given magnitude of gradient, longitudinally, and in response to therapy. The mid-systolic drop could act as a biomarker of contractile reserve. Currently, clinical application of metabolic resonance spectroscopy is limited by long acquisition times and low applicability of the technique for individual patients. Improved and shorter protocols, as well as developments allowing measurement of abnormal metabolic flux (rather than steady state levels of metabolites) might increase the clinical relevance of this technique. In the future, the magnitude of energetic impairment might provide prognostic information in both heart failure and sudden death. Otherwise MR spectroscopy might be used to identify which patients with mid-LV obstruction are at highest risk of apical aneurysm, or inform counselling of individual patients about intense exercise, which is a challenging area with limited evidence. Finally, the concept of energetic insufficiency as a central mechanism in the pathophysiology of obstructive and nonobstructive HCM opens up new areas for potential pharmacological intervention, particularly for patients with nonobstructive disease, for whom current therapeutic options for relief of severe symptoms are very limited.
